Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer

Completed · Phase 2

Conditions studied: Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Oral Complications, Radiation Toxicity

In brief

RATIONALE: Keratinocyte growth factor may prevent symptoms of mucositis in patients receiving radiation therapy and chemotherapy. PURPOSE: Randomized phase II trial to study the effectiveness of keratinocyte growth factor in preventing oral mucositis in patients who have hematologic cancers and who are undergoing radiation therapy and chemotherapy before autologous peripheral stem cell transplantation.

Key facts

Study ID

NCT00004132

Run by

Jonsson Comprehensive Cancer Center

Starts

2000-01-01

Expected to finish

2004-05-01

Last updated by the study team

2013-06-26

Who can join

Age: 12 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Jonsson Comprehensive Cancer Center, UCLA — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.